Multicare Health System Institute for Research and Innovation

Tacoma, Washington 98405

1 studies enrolling now · 20 studies all time

What they study most

Anemia, Breast Cancer, COVID-19, Constipation - Functional, Crohn's Disease, Diabetes Mellitus, Type 2, Dravet Syndrome, Genetic Obesity, Growth Hormone Deficiency, Iron-deficiency, Metastatic Colorectal Cancer, Metastatic Pancreatic Adenocarcinoma

Studies at this site

• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Recruiting now
• EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway — Completed
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) — Running, not enrolling
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] — Completed
• An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome — Running, not enrolling
• Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years — Completed
• A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis — Completed
• MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) — Completed
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• Phase 3 Alogliptin Pediatric Study — Completed
• Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients — Completed
• Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) — Completed
• Lubiprostone in Children With Functional Constipation — Completed
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• Lubiprostone for Children With Constipation — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• ACTH for Fatigue in Multiple Sclerosis Patients — Completed
• A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency — Completed